Our top pick for
AC Immune SA is a biotechnology business based in the US. AC Immune shares (ACIU) are listed on the NASDAQ and all prices are listed in US Dollars. AC Immune employs 115 staff and has a market cap (total outstanding shares value) of USD$395.3 million.
|Latest market close||USD$6.41|
|52-week range||USD$4.07 - USD$10.14|
|50-day moving average||USD$5.2388|
|200-day moving average||USD$6.2518|
|Wall St. target price||USD$12.15|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.547|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||6.41|
|1 month (2020-12-18)||16.76%|
|3 months (2020-10-16)||31.35%|
|6 months (2020-07-17)||-22.58%|
|1 year (2020-01-17)||-30.33%|
|2 years (2019-01-18)||-43.47%|
|3 years (2018-01-18)||13.06|
|5 years (2016-01-15)||N/A|
Valuing AC Immune stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AC Immune's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AC Immune's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, AC Immune shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$60.6 million|
|Return on assets TTM||-13.25%|
|Return on equity TTM||-23.54%|
|Market capitalisation||USD$395.3 million|
TTM: trailing 12 months
There are currently 1.5 million AC Immune shares held short by investors – that's known as AC Immune's "short interest". This figure is 11% down from 1.7 million last month.
There are a few different ways that this level of interest in shorting AC Immune shares can be evaluated.
AC Immune's "short interest ratio" (SIR) is the quantity of AC Immune shares currently shorted divided by the average quantity of AC Immune shares traded daily (recently around 253685.88640275). AC Immune's SIR currently stands at 5.81. In other words for every 100,000 AC Immune shares traded daily on the market, roughly 5810 shares are currently held short.
However AC Immune's short interest can also be evaluated against the total number of AC Immune shares, or, against the total number of tradable AC Immune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AC Immune's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 AC Immune shares in existence, roughly 20 shares are currently held short) or 0.0476% of the tradable shares (for every 100,000 tradable AC Immune shares, roughly 48 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AC Immune.
Find out more about how you can short AC Immune stock.
We're not expecting AC Immune to pay a dividend over the next 12 months.
Over the last 12 months, AC Immune's shares have ranged in value from as little as $4.07 up to $10.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AC Immune's is 0.8292. This would suggest that AC Immune's shares are less volatile than average (for this exchange).
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.